In two murine models for colitis, we recently showed that the administration of a semi-synthetic FXR agonist ameliorates intestinal inflammation, with improvement of colitis symptoms, preservation of intestinal barrier function, reduced goblet cell loss and inhibition of proinflammatory cytokine expression [11]. Here, NR1H4 is linked to colitis.